Garth Rapeport joined F-Prime in 2021 as an Entrepreneur-in-Residence on the healthcare team. Garth is visiting Professor at the National Heart & Lung Institute, Imperial College School of Medicine in London. He was previously co-founder and CEO of Pulmocide and Respivert Ltd. which were drug discovery companies focused on the identification of novel disease modifying treatments for severe asthma and new generation inhaled antiviral and antifungal agents.
Garth is a medical graduate who undertook post-graduate training at the Universities of Glasgow and Oxford. After working at Pfizer Research in the UK he moved to GSK where he was SVP of Drug Discovery in the Respiratory area in which he led the discovery and early development new inhaled therapies for asthma and COPD.